OVID Stock Forecast: Ovid Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.20
−5.98% on the day

The 13 Wall Street analysts covering Ovid Therapeutics, Inc. hold a median 12-month price target of $5.25 — +138.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 47 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$415.2M
Ticker Nerd rank
47/ 100
Median analyst target
$5.25
Analysts covering
13
Revenue$733K−88.3% y/y
Operating income−$15.7M
Net income−$15.0M
Free cash flow−$17.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.4%
1M
−6.8%
YTD
+35.0%
1Y
+80.3%
From 52W high
−25.7%
From 52W low
+80.3%
$1.22
$2.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Ovid Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
47/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
87
Quality
74
Value
53
Growth
47
Revisions
46
Volatility
35
Issuance
35
Accruals
15

Momentum (87): The shares have been drifting up relative to others.

Accruals (15): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OVID stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OVID, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26OVIDHigh $9.00Median $5.25Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
13
Buy
0
Hold
0
Sell
$4.00
Low
$5.25
Median
$9.00
High

The green dot is the last close — the median target sits +138.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
15 Oct 2026Wolfe ResearchInitiatesOutperform$5.00
9 Oct 2026Cantor FitzgeraldInitiatesOverweight—
6 Oct 2026GuggenheimInitiatesBuy$7.00
5 Oct 2026GuggenheimInitiatesBuy$7.00
11 Sept 2026HC Wainwright & Co.MaintainsBuy$4.00 → $5.00
3 Aug 2026OppenheimerMaintainsOutperform$7.00 → $9.00
15 Apr 2026WedbushReiteratesOutperform$7.00
9 Apr 2026HC Wainwright & Co.MaintainsBuy$2.00 → $4.00
26 Mar 2026BTIGReiteratesBuy—
20 Mar 2026WedbushMaintainsOutperform—
22 Dec 2025HC Wainwright & Co.ReiteratesBuy—
22 Dec 2025LifeSci CapitalInitiatesOutperform—
11 Dec 2025Roth CapitalInitiatesBuy—
24 Nov 2025HC Wainwright & Co.MaintainsBuy—
17 Nov 2025Leerink PartnersInitiatesOutperform—
27 May 2025HC Wainwright & Co.MaintainsBuy—
24 Mar 2025BTIGMaintainsBuy—
24 Mar 2025HC Wainwright & Co.MaintainsBuy—
12 Mar 2025WedbushMaintainsOutperform—
29 Jan 2025OppenheimerUpgradeOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OVID.

Market Radar

This page is one stock. Monday covers all of them.

OVID appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

OVID vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Ovid Therapeutics, Inc. returned +80.3% against +6.9% for the S&P 500, dividends included.

OVID vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26OVIDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OVID analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
7
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
285.8×

Cheaper than 2% of US stocks

Price / book
2.1×

Cheaper than 42% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−88.3%

Higher than 2% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−35.4%

Higher than 26% of US stocks

Return on assets
−29.8%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ovid Therapeutics, Inc. has a market value of $415.2M and an enterprise value of $291.0M.

  • Revenue in the twelve months to 30 June 2026: $1.6M. The latest quarter shrank 88.3% year on year.

  • Net income over the same four quarters: −$34.5M, a −2178.9% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.31.

  • Free cash flow in the twelve months to 30 June 2026: −$54.8M.

  • Shares outstanding: 184.8M.

  • Ovid Therapeutics, Inc. employs 23 people — $69K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

OVID and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OVIDOvid Therapeutics, Inc.$415.2M47
CRMDCorMedix, Inc.$410.8M63
TECXTectonic Therapeutic, Inc.$413.5M44
TVGNTevogen, Inc.$405.2M17
ARVNArvinas, Inc.$423.0M74
CADLCandel Therapeutics, Inc.$395.4M43
AVTXAvalo Therapeutics, Inc.$390.9M29

Take a look at OVID’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Ovid Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about OVID

What is the OVID stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Ovid Therapeutics, Inc. have a median 12-month price target of $5.25, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OVID stock a buy right now?

Of the 13 analysts covering Ovid Therapeutics, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ovid Therapeutics, Inc. 47 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OVID?

As at 21 Nov 2026, Ovid Therapeutics, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (87 of 100).

Will OVID stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +138.6% from the last close, and Ticker Nerd's factor model ranks Ovid Therapeutics, Inc. 47 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OVID stock forecast for 2030?

No analyst covering Ovid Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OVID are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.

How has OVID stock performed over the past year?

Ovid Therapeutics, Inc. returned +80.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ovid Therapeutics, Inc. do?

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain disorders, with an emphasis on epilepsies and other seizure-related neurological conditions. The company’s current pipeline centers on therapies designed to address significant unmet needs in central nervous system diseases, including OV329, a GABA-AT inhibitor in clinical development, and OV4071, an oral KCC2 activator being studied for select neuropsychiatric and neurological indications.

Company

About Ovid Therapeutics, Inc.

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain disorders, with an emphasis on epilepsies and other seizure-related neurological conditions. The company’s current pipeline centers on therapies designed to address significant unmet needs in central nervous system diseases, including OV329, a GABA-AT inhibitor in clinical development, and OV4071, an oral KCC2 activator being studied for select neuropsychiatric and neurological indications. Ovid Therapeutics works at the intersection of drug discovery and clinical development, advancing mechanism-based programs aimed at rare and complex disorders where treatment options remain limited. Its role in the market is to identify differentiated candidates for neurological and neuropsychiatric diseases and progress them through early-stage testing toward potential therapeutic use.

CEO Ms. Margaret Alexander · 23 employees · United States · https://www.ovidrx.com